$1.37
+0.01(0.74%)
Mkt Cap $48M
$1.12
$2.50
52-Week Range
At a Glance
AI-generatedA critical inflection year marked by accelerating losses and near-exhaustion of liquidity as the company advanced its lead asset toward regulatory submission, though positive Phase IIb survival data provides a path to potential approval.
8-K
OS Therapies completed a $5.25M registered direct offering on April 2, 2026, issuing common stock and pre-funded warrants alongside common and placement agent warrants, generating $4.7M in net proceeds to fund clinical development, R&D, and general corporate purposes.$48M
Market Cap
—
Revenue
—
Net Income
Employees4
Fundamentals
How The Business Makes Money
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001795091
ISINUS68764Y2072
Phone410-297-7793
Address115 Pullman Crossing Road, Rockville, MD, 21638, US
SEC EDGAR